Satoshi Fujii
About
Satoshi Fujii is a scholar working on Cancer Research, Molecular Biology and Cardiology and Cardiovascular Medicine.
According to data from OpenAlex, Satoshi Fujii has authored 149 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Cancer Research, 31 papers in Molecular Biology and 30 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Satoshi Fujii's work include Protease and Inhibitor Mechanisms (31 papers), Blood Coagulation and Thrombosis Mechanisms (15 papers) and Antibiotics Pharmacokinetics and Efficacy (12 papers). Satoshi Fujii is often cited by papers focused on Protease and Inhibitor Mechanisms (31 papers), Blood Coagulation and Thrombosis Mechanisms (15 papers) and Antibiotics Pharmacokinetics and Efficacy (12 papers). Satoshi Fujii collaborates with scholars based in Japan, United States and Germany. Satoshi Fujii's co-authors include Burton E. Sobel, Hirofumi Sawa, Izumi Negishi, Noboru Motoyama, Keiko Nakayama, Kei-ichi Nakayama, Kevin A. Roth, Qing Zhang, Fanping Wang and Dennis Y. Loh and has published in prestigious journals such as Science, Journal of Biological Chemistry and Circulation.
In The Last Decade
Satoshi Fujii
146 papers receiving 4.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Satoshi Fujii Japan | 35 | 1.9k | 797 | 673 | 624 | 604 | 149 | 4.5k | ||
| John S. Mudgett United States | 33 | 1.8k 1.0× | 933 1.2× | 1.4k 2.0× | 339 0.5× | 778 1.3× | 49 | 5.6k | ||
| Yoshitake Hayashi Japan | 36 | 1.8k 1.0× | 539 0.7× | 778 1.2× | 587 0.9× | 1.5k 2.6× | 243 | 5.6k | ||
| Peter Liu Canada | 30 | 1.7k 0.9× | 393 0.5× | 716 1.1× | 1.8k 2.8× | 933 1.5× | 76 | 4.8k | ||
| Janice Russell United States | 39 | 1.4k 0.8× | 231 0.3× | 903 1.3× | 368 0.6× | 518 0.9× | 109 | 4.2k | ||
| Heng Lin Taiwan | 43 | 2.9k 1.6× | 920 1.2× | 1.2k 1.8× | 331 0.5× | 1.1k 1.8× | 135 | 5.4k | ||
| Sabina Janciauskiene Sweden | 47 | 2.1k 1.1× | 1.8k 2.3× | 1.1k 1.6× | 260 0.4× | 560 0.9× | 176 | 6.5k | ||
| Ping Qiu United States | 36 | 1.8k 0.9× | 417 0.5× | 711 1.1× | 348 0.6× | 2.4k 4.0× | 156 | 7.1k | ||
| Eli C. Lewis Israel | 31 | 1.6k 0.9× | 688 0.9× | 1.1k 1.6× | 183 0.3× | 491 0.8× | 92 | 4.2k | ||
| Viktória Jeney Hungary | 35 | 3.0k 1.6× | 319 0.4× | 631 0.9× | 214 0.3× | 419 0.7× | 72 | 5.9k | ||
| Mariano Sánchez Crespo Spain | 38 | 1.4k 0.8× | 302 0.4× | 1.3k 1.9× | 365 0.6× | 464 0.8× | 140 | 4.0k |
Countries citing papers authored by Satoshi Fujii
Since
Specialization
Citations
This map shows the geographic impact of Satoshi Fujii's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoshi Fujii with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoshi Fujii more than expected).
Fields of papers citing papers by Satoshi Fujii
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Satoshi Fujii. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoshi Fujii. The network helps show where Satoshi Fujii may publish in the future.
Co-authorship network of co-authors of Satoshi Fujii
This figure shows the co-authorship network connecting the top 25 collaborators of Satoshi Fujii. A scholar is included among the top collaborators of Satoshi Fujii based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoshi Fujii. Satoshi Fujii is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ishigo, Tomoyuki, Toshiyuki Yano, Masayuki Koyama, et al.. (2023). Comparison of the Treatment Persistence Among 4 Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A 5‐Year Retrospective Cohort Study. The Journal of Clinical Pharmacology. 63(6). 654–663.
2.
Matsumoto, Kazuaki, Kazutaka Oda, Kensuke Shoji, et al.. (2022). Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Pharmaceutics. 14(3). 489–489.
3.
Takesue, Yoshio, Yuki Hanai, Kazutaka Oda, et al.. (2022). Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Clinical Therapeutics. 44(12). 1604–1623.
4.
Hanai, Yuki, Yukihiro Hamada, Toshimi Kimura, et al.. (2021). Favorable Effects of Voriconazole Trough Concentrations Exceeding 1 μg/mL on Treatment Success and All-Cause Mortality: A Systematic Review and Meta-Analysis. Journal of Fungi. 7(4). 306–306.
5.
Hanai, Yuki, Yoshiko Takahashi, Takashi Niwa, et al.. (2021). Optimal trough concentration of teicoplanin for the treatment of methicillin‐resistant Staphylococcus aureus infection: A systematic review and meta‐analysis. Journal of Clinical Pharmacy and Therapeutics. 46(3). 622–632.
6.
Mizukami, Yuki, Yuki Enoki, Kazuaki Taguchi, et al.. (2021). The optimal trough-guided monitoring of vancomycin in children: Systematic review and meta-analyses. Journal of Infection and Chemotherapy. 27(5). 781–785.
7.
Hanai, Yuki, Yukihiro Hamada, Toshimi Kimura, et al.. (2020). Optimal trough concentration of voriconazole with therapeutic drug monitoring in children: A systematic review and meta-analysis. Journal of Infection and Chemotherapy. 27(2). 151–160.
8.
Ichihara, Koji, et al.. (2020). Pharmacokinetics of Testosterone Enanthate After Intramuscular Injection for Transgender Men. 1(1). 15–21.
9.
Sugiura, Tomonori, Yasuaki Dohi, Hiroyuki Takase, Satoshi Fujii, & Nobuyuki Ohte. (2018). Findings relevant to the QRS wave in the resting electrocardiogram are associated with circulating concentrations of high-sensitivity cardiac troponin I in the general population. Journal of the American Society of Hypertension. 12(8). 614–620.
10.
Ando, Katsuyoshi, Mikihiro Fujiya, Yoshiki Nomura, et al.. (2018). The Incidence and Risk Factors of Venous Thromboembolism in Patients with Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study. Digestion. 100(4). 229–237.
11.
Ikeda, Hiroshi, et al.. (2016). Plasma tenofovir trough concentrations are associated with renal dysfunction in Japanese patients with HIV infection: a retrospective cohort study. Journal of Pharmaceutical Health Care and Sciences. 2(1). 22–22.
12.
Iwaki, Soichiro, et al.. (2016). Sphingosine 1-phosphate induced by hypoxia increases the expression of PAI-1 in HepG2 cells via HIF-1α. Molecular Medicine Reports. 14(2). 1841–1848.
13.
Yoshinaga, Keiichiro, Hiroshi Ohira, Ichizo Tsujino, et al.. (2014). Attenuated right ventricular energetics evaluated using 11C-acetate PET in patients with pulmonary hypertension. European Journal of Nuclear Medicine and Molecular Imaging. 41(6). 1240–1250.
14.
Sun, Xiao, et al.. (2012). Circulating microRNA-126 in patients with coronary artery disease: correlation with LDL cholesterol. Thrombosis Journal. 10(1). 16–16.
15.
Takeda, Kotaro, Toshihiro Ichiki, Tomotake Tokunou, et al.. (2000). Critical Roles of Rho Kinase and Mek/Erk Pathways for Angiotensin Ii-Induced Plasminogen Activator Inhibitor-1 Gene Expression. Hypertension. 36. 721–721.
16.
Furumoto, Tomoo, et al.. (2000). Diminished Endothelial Function and Hypofibrinolysis in High Risk Patients with Hypertension and High Plasma Levels of Inflammatory Markers: Need for Anti-Inflammatory Strategy. Hypertension. 36. 684–685.
17.
Shuto, Takashi, Toshiyuki Yoshida, Satoshi Fujii, & Isao Yamamoto. (2000). Current Therapeutic Strategy for Asymptomatic Cerebral Aneurysms in Japan. Surgery for Cerebral Stroke. 28(1). 1–5.
18.
Motoyama, Noboru, Fanping Wang, Kevin A. Roth, et al.. (1995). Massive Cell Death of Immature Hematopoietic Cells and Neurons in Bcl-x-Deficient Mice. Science. 267(5203). 1506–1510.
19.
Fujii, Satoshi, et al.. (1986). Studies on Improvement of Quality of Sago Starch. Part II. Effect of the Manufacturing Condition on the Quality of Sago Starch. Kobe University Repository Kernel (Kobe University). 17(1). 97–106.
20.
Fujii, Satoshi, et al.. (1983). Mechanism of membrane-permeation of coloring matters in ultrafiltration of caramel solution.. MEMBRANE. 8(6). 365–370.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by John S. Mudgett Breakdown of academic impact, for papers by Yoshitake Hayashi Breakdown of academic impact, for papers by Peter Liu Breakdown of academic impact, for papers by Janice Russell Breakdown of academic impact, for papers by Heng Lin Breakdown of academic impact, for papers by Sabina Janciauskiene Breakdown of academic impact, for papers by Ping Qiu Breakdown of academic impact, for papers by Eli C. Lewis Breakdown of academic impact, for papers by Viktória Jeney Breakdown of academic impact, for papers by Mariano Sánchez Crespo